Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s blockbuster diabetes and weight loss drugs start expiring as soon as next year.
The FTSE 100 group is racing to produce a generic form of semaglutide, the active ingredient in the drugs. Patents on the branded versions are…
Read the full article here
